Last reviewed · How we verify
single dose Nevirapine — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
single dose Nevirapine (single dose Nevirapine) — National Institute of Allergy and Infectious Diseases (NIAID).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| single dose Nevirapine TARGET | single dose Nevirapine | National Institute of Allergy and Infectious Diseases (NIAID) | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- single dose Nevirapine CI watch — RSS
- single dose Nevirapine CI watch — Atom
- single dose Nevirapine CI watch — JSON
- single dose Nevirapine alone — RSS
Cite this brief
Drug Landscape (2026). single dose Nevirapine — Competitive Intelligence Brief. https://druglandscape.com/ci/single-dose-nevirapine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing